Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations

Study Overview
=================
Brief Summary
-----------------
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.

Official Title
-----------------
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations

Conditions
-----------------
Carcinoma, Renal Cell

Intervention / Treatment
-----------------
* Other: Blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers Age ≥ 18 years old and able to provide written informed consent; Have not received any systemic or topical treatment for kidney/liver tumors. Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements. Exclusion Criteria: The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc. The subjects is known or suspected of other malignancies. There has been another history of malignancy in the past 5 years. Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Renal cancer group<br>Patients which imaging studies have found renal mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100. | Other: Blood test<br>* About 4 ml of blood draw<br>|
| Urothiasis group<br>Patients which imaging studies have found renal or ureteral stones, and rule out of renal mass, about 100. | Other: Blood test<br>* About 4 ml of blood draw<br>|
| Renal cysts group<br>Patients which imaging studies have found renal cysts (simple or complex) about 100. | Other: Blood test<br>* About 4 ml of blood draw<br>|
| Liver cancer group<br>Patients which imaging studies have found hepatic mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100. | Other: Blood test<br>* About 4 ml of blood draw<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NMAP level study | To observe the difference in the expression level of nicotinamide metabolism related protein (NMAP) in the serum of newly diagnosed renal cancer and non-renal cancer patients. Draw the NMAP ROC curve and establish the appropriate Cut-off value to analyze its sensitivity and specificity. | September 2019-September 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NMAP plus other tumor biomarkers study | According to NMAP and combined with other tumor biomarkers data such as AFP, multiple regression analysis was used to map the ROC curve and establish the appropriate Cut-off value to determine whether it is capable of distinguishing kidney cancer and liver cancer. | September 2019-September 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renal cancer, tumor biomarker